CA1302279C - Solid dispersion composition of fr-900506 substance - Google Patents

Solid dispersion composition of fr-900506 substance

Info

Publication number
CA1302279C
CA1302279C CA000533582A CA533582A CA1302279C CA 1302279 C CA1302279 C CA 1302279C CA 000533582 A CA000533582 A CA 000533582A CA 533582 A CA533582 A CA 533582A CA 1302279 C CA1302279 C CA 1302279C
Authority
CA
Canada
Prior art keywords
substance
solid dispersion
dispersion composition
water
liters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000533582A
Other languages
English (en)
French (fr)
Inventor
Yoshio Ueda
Fumio Shimojo
Yasuo Shimazaki
Kazutake Kado
Toshiyasu Honbo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of CA1302279C publication Critical patent/CA1302279C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Reinforced Plastic Materials (AREA)
  • Colloid Chemistry (AREA)
CA000533582A 1986-04-02 1987-04-01 Solid dispersion composition of fr-900506 substance Expired - Lifetime CA1302279C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868608080A GB8608080D0 (en) 1986-04-02 1986-04-02 Solid dispersion composition
GB8608080 1986-04-02

Publications (1)

Publication Number Publication Date
CA1302279C true CA1302279C (en) 1992-06-02

Family

ID=10595572

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000533582A Expired - Lifetime CA1302279C (en) 1986-04-02 1987-04-01 Solid dispersion composition of fr-900506 substance

Country Status (16)

Country Link
US (1) US4916138A (OSRAM)
EP (1) EP0240773B1 (OSRAM)
JP (1) JPS62277321A (OSRAM)
KR (2) KR950007209B1 (OSRAM)
AT (1) ATE73327T1 (OSRAM)
CA (1) CA1302279C (OSRAM)
DE (1) DE3777223D1 (OSRAM)
DK (1) DK174979B1 (OSRAM)
ES (1) ES2032397T3 (OSRAM)
GB (1) GB8608080D0 (OSRAM)
GR (1) GR3004124T3 (OSRAM)
HK (1) HK6397A (OSRAM)
IE (1) IE59712B1 (OSRAM)
MX (1) MX9202945A (OSRAM)
RU (1) RU1826977C (OSRAM)
UA (1) UA13209A (OSRAM)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
JPH02206A (ja) * 1987-11-11 1990-01-05 Fujisawa Pharmaceut Co Ltd エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
ES2043766T3 (es) * 1987-11-11 1994-01-01 Pharmascience Lab Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua.
FR2640137A1 (fr) * 1988-12-08 1990-06-15 Texinfine Sa Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention
ATE117897T1 (de) * 1989-07-05 1995-02-15 Fujisawa Pharmaceutical Co Wässriges flüssiges mittel zur äusserlichen anwendung.
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
WO1992001453A1 (fr) * 1990-07-19 1992-02-06 Otsuka Pharmaceutical Co., Ltd. Preparation solide
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
ES2134860T3 (es) * 1992-11-18 1999-10-16 Fujisawa Pharmaceutical Co Preparacion farmaceutica de accion prolongada.
DE4316537A1 (de) * 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
JP3362394B2 (ja) 1995-09-19 2003-01-07 藤沢薬品工業株式会社 エアゾール組成物
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
CA2284988A1 (en) 1997-04-11 1998-10-22 Fujisawa Pharmaceutical Co., Ltd. Medicinal composition
HRP20000707B1 (en) * 1998-03-26 2005-06-30 Fujisawa Pharmaceutical Co. Sustained release preparations
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
AU768220B2 (en) * 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US7572788B2 (en) * 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
EP2062583B1 (en) 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
AU2001238476A1 (en) 2000-02-18 2001-08-27 Kosan Biosciences, Inc. Motocide compounds
US6750047B2 (en) * 2000-08-21 2004-06-15 Kosan Biosciences, Inc. Fermentation and purification of migrastatin and analog
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US6989131B2 (en) * 2002-03-12 2006-01-24 Uop Llc Catalytic reactor with integral evaporator
CN100363359C (zh) * 2002-08-29 2008-01-23 菲塞股份有限公司 运动内酯化合物
EP1641437A4 (en) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
CN1859909B (zh) * 2003-08-29 2011-04-06 生命周期药物公司 含有他克莫司的固态分散体
JP4996249B2 (ja) 2003-08-29 2012-08-08 ベロクシス ファーマシューティカルズ エー／エス タクロリムスを含む改質放出組成物
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
AU2006203946B2 (en) * 2005-01-03 2009-07-23 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
US20070043033A1 (en) 2005-06-01 2007-02-22 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
WO2007053725A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
NZ573452A (en) 2006-06-09 2011-09-30 Univ Michigan Compositions and methods relating to novel compounds and targets thereof
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
EP2119442A4 (en) 2006-12-28 2010-12-15 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
CA2783589A1 (en) * 2007-03-09 2008-09-18 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
WO2009036175A2 (en) 2007-09-14 2009-03-19 The Regents Of The University Of Michigan F1f0-atpase inhibitors and related methods
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
KR20100083819A (ko) 2007-11-06 2010-07-22 더 리젠츠 오브 더 유니버시티 오브 미시간 피부 병태의 치료에 유용한 벤조디아제피논 화합물
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
KR101003042B1 (ko) 2008-03-17 2010-12-21 종근당바이오 주식회사 고순도 타크로리무스의 정제 방법
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
AU2009291632B2 (en) 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
JP2013505258A (ja) 2009-09-18 2013-02-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ベンゾジアゼピノン化合物およびそれを使用する治療方法
CN102753179A (zh) 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
RS55118B1 (sr) 2010-02-17 2016-12-30 Veloxis Pharmaceuticals As Stabilizovana takrolimus kompozicija
PT2579858E (pt) 2010-06-14 2014-07-18 Ratiopharm Gmbh Composição farmacêutica que contém ivabradina
WO2012026896A1 (en) 2010-08-25 2012-03-01 Les Laboratoires Medis Sa Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
KR101243938B1 (ko) * 2010-10-19 2013-03-19 이희엽 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
CN104364329B (zh) 2012-04-11 2016-08-17 陶氏环球技术有限责任公司 包含有机稀释剂和纤维素醚的组合物
WO2015047763A1 (en) * 2013-09-25 2015-04-02 Dow Global Technologies Llc Composition comprising an organic liquid diluent and a specific hydroxyalkyl methylcellulose
US20170072058A1 (en) * 2014-11-21 2017-03-16 Solipharma Llc Pharmaceutical composition containing tacrolimus and preparation methods thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (OSRAM) * 1963-10-11
DE1492034A1 (de) * 1965-05-18 1969-02-20 Merck Ag E Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same

Also Published As

Publication number Publication date
GB8608080D0 (en) 1986-05-08
MX9202945A (es) 1992-07-01
DK140487D0 (da) 1987-03-18
KR950007209B1 (ko) 1995-07-04
KR950007210B1 (ko) 1995-07-04
EP0240773B1 (en) 1992-03-11
JPH0536411B2 (OSRAM) 1993-05-31
US4916138A (en) 1990-04-10
KR870010073A (ko) 1987-11-30
GR3004124T3 (OSRAM) 1993-03-31
DE3777223D1 (de) 1992-04-16
HK6397A (en) 1997-01-24
DK140487A (da) 1987-10-03
DK174979B1 (da) 2004-04-05
ATE73327T1 (de) 1992-03-15
EP0240773A1 (en) 1987-10-14
KR890001626A (ko) 1989-03-28
RU1826977C (ru) 1993-07-07
ES2032397T3 (es) 1993-02-16
IE59712B1 (en) 1994-03-23
UA13209A (uk) 1997-02-28
JPS62277321A (ja) 1987-12-02
IE870843L (en) 1987-10-02

Similar Documents

Publication Publication Date Title
CA1302279C (en) Solid dispersion composition of fr-900506 substance
CA1334391C (en) Immunosuppressant compound
KR930010708B1 (ko) 트리사이클로 화합물의 제조방법
Hatanaka et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces II. Fermentation, isolation and physico-chemical and biological characteristics
CA1334392C (en) Immunosuppressant agent
EP0510903A1 (en) Novel lipophilic macrolide useful as an immunosuppressant
JP2917305B2 (ja) Ｆｒ−９０１１５５物質およびその生産法
JPH078873B2 (ja) 免疫抑制剤として有効な新規の親油性マクロライド
PL179581B1 (pl) kompozycja farmaceutyczna oraz substancja farmakologicznie czynna PL PL PL PL PL PL PL PL
JPH0320279A (ja) 新規免疫抑制剤
EP1751272A2 (en) Production of tacrolimus (fk-506) using new streptomyces species
EP0378321A2 (en) Microbial transformation product of L-683-590
CZ279307B6 (cs) Rebeccamycinový analog, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
GB2263112A (en) New cyclic fr-900520 microbial biotransformation agent
US5359060A (en) Phosponated derivatives of macrolides
EP0818464B1 (en) Methylsulfomycin l, a process for its production and its use
EP0396400A1 (en) Microbial transformation product
US5268370A (en) Microbial transformation product of L-679,934
EP0501399A1 (en) Physiologically active kanglemycin C, process for preparing the same and use thereof
EP0378317A2 (en) Microbial transformation product of L-679,934
EP0378320A2 (en) Microbial transformation product
JPH05155885A (ja) 新規ｈｐ５３０ｃ２ 物質及びその製造法

Legal Events

Date Code Title Description
MKEX Expiry